Skip to main content
. 2021 Nov 2;67(8):4008–4019. doi: 10.1007/s10620-021-07273-y

Table 2.

Primary outcome: clinical benefit, n (%)

LDAA patients AZAm patients p-value
Clinical benefit at 6 months 116/156 (74%) 59/111 (53%) 0.0003
Clinical benefit at 12 months 74/138 (54%) 38/103 (37%) 0.01
Clinical benefit in the long-term (≥ 12 months) 51/138 (37%) 25/103 (24%) 0.04